{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T02:49:02Z","timestamp":1792550942909,"version":"4.5.0"},"reference-count":54,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2022,6,16]],"date-time":"2022-06-16T00:00:00Z","timestamp":1655337600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100004410","name":"T\u00fcrkiye Bilimsel ve Teknolojik Ara\u015ftirma Kurumu","doi-asserted-by":"publisher","award":["215S750"],"award-info":[{"award-number":["215S750"]}],"id":[{"id":"10.13039\/501100004410","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81850410547"],"award-info":[{"award-number":["81850410547"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"abstract":"<jats:p>Follicular lymphoma (FL) is the second most frequent non-Hodgkin lymphoma accounting for 10-20% of all lymphomas in western countries. As a clinically heterogeneous cancer, FL occasionally undergoes histological transformation to more aggressive B cell lymphoma types that are associated with poor prognosis. Here we evaluated the potential of circulating cell-free DNA (cfDNA) to improve the diagnosis and prognosis of follicular lymphoma patients. Twenty well-characterized FL cases (13 symptomatic and 7 asymptomatic) were prospectively included in this study. Plasma cfDNA, formalin-fixed paraffin-embedded (FFPE) tumor tissue DNA, and patient-matched granulocyte genomic DNA samples were obtained from 20 treatment-naive FL cases. Ultra-deep targeted next-generation sequencing was performed with these DNA samples by using a custom-designed platform including exons and exon-intron boundaries of 110 FL related genes. Using a strict computational bioinformatics pipeline, we identified 91 somatic variants in 31 genes in treatment-naive FL cases. Selected variants were cross-validated by using PCR-Sanger sequencing. We observed higher concentrations of cfDNA and a higher overlap of somatic variants present both in cfDNA and tumor tissue DNA in symptomatic FL cases compared to asymptomatic ones. Variants known to be associated with FL pathogenesis such as STAT6 p.D419 or EZH2 p.Y646 were observed in patient-matched cfDNA and tumor tissue samples. Consistent with previous observations, high Ki-67 staining, elevated LDH levels, FDG PET\/CT positivity were associated with poor survival. High plasma cfDNA concentrations or the presence of <jats:italic>BCL2<\/jats:italic> mutations in cfDNA showed significant association with poor survival in treatment-naive patients. <jats:italic>BCL2<\/jats:italic> mutation evaluations in cfDNA improved the prognostic utility of previously established variables. In addition, we observed that a FL patient who had progressive disease contained histological transformation-associated gene (i.e. <jats:italic>B2M<\/jats:italic> and <jats:italic>BTG1<\/jats:italic>) mutations only in cfDNA. Pre-treatment concentrations and genotype of plasma cfDNA may be used as a liquid biopsy to improve diagnosis, risk stratification, and prediction of histological transformation. Targeted therapies related to oncogenic mutations may be applied based on cfDNA genotyping results. However, the results of this study need to be validated in a larger cohort of FL patients as the analyses conducted in this study have an exploratory nature.<\/jats:p>","DOI":"10.3389\/fonc.2022.870487","type":"journal-article","created":{"date-parts":[[2022,6,16]],"date-time":"2022-06-16T04:47:31Z","timestamp":1655354851000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":15,"title":["Plasma Concentrations and Cancer-Associated Mutations in Cell-Free Circulating DNA of Treatment-Naive Follicular Lymphoma for Improved Non-Invasive Diagnosis and Prognosis"],"prefix":"10.3389","volume":"12","author":[{"given":"Tevfik","family":"Hatipo\u011flu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Esra","family":"Esmeray S\u00f6nmez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaozhou","family":"Hu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hongling","family":"Yuan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ay\u00e7a Er\u015fen","family":"Danyeli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ahmet","family":"\u015eeyhanl\u0131","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tu\u011fba","family":"\u00d6nal-S\u00fczek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Weiwei","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Burcu","family":"Akman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ayb\u00fcke","family":"Olgun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sermin","family":"\u00d6zkal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"\u0130nci","family":"Alacac\u0131o\u011flu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mehmet Ali","family":"\u00d6zcan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hua","family":"You","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Can","family":"K\u00fc\u00e7\u00fck","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2022,6,16]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.3322\/CAAC.21357","article-title":"US Lymphoid Malignancy Statistics by World Health Organization Subtypes","volume":"66","author":"Teras","year":"2016","journal-title":"CA Cancer J Clin"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1038\/nrc1589","article-title":"Mechanisms of B-Cell Lymphoma Pathogenesis","volume":"5","author":"K\u00fcppers","year":"2005","journal-title":"Nat Rev Cancer"},{"key":"B3","doi-asserted-by":"publisher","first-page":"3","DOI":"10.3960\/JSLRT.54.3","article-title":"Pathology of Follicular Lymphoma","volume":"54","author":"Takata","year":"2014","journal-title":"J Clin Exp Hematop"},{"key":"B4","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1038\/LEU.2016.175","article-title":"Combined Copy Number and Mutation Analysis Identifies Oncogenic Pathways Associated With Transformation of Follicular Lymphoma","volume":"31","author":"Bouska","year":"2017","journal-title":"Leukemia"},{"key":"B5","doi-asserted-by":"publisher","first-page":"vi59","DOI":"10.1093\/ANNONC\/MDR388","article-title":"Newly Diagnosed and Relapsed Follicular Lymphoma: ESMO Clinical Practice Guidelines for Diagnosis, Treatment and Follow-Up","author":"Dreyling","year":"2011","journal-title":"Ann Oncol Off J Eur Soc Med Oncol"},{"key":"B6","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3906\/biy-1908-23","article-title":"Genetic Alterations in B Cell Lymphoma Subtypes as Potential Biomarkers for Noninvasive Diagnosis, Prognosis, Therapy, and Disease Monitoring","volume":"44","author":"Esmeray","year":"2020","journal-title":"Turk J Biol"},{"key":"B7","doi-asserted-by":"publisher","first-page":"2687\u201490","DOI":"10.1182\/blood-2018-03-837039","article-title":"CREBBP Gene Mutations Are Frequently Detected in in Situ Follicular Neoplasia","volume":"132","author":"Schmidt","year":"2018","journal-title":"Blood"},{"key":"B8","doi-asserted-by":"publisher","first-page":"369\u2014377","DOI":"10.1002\/path.5861","article-title":"Widespread in Situ Follicular Neoplasia in Patients Who Subsequently Developed Follicular Lymphoma","volume":"256","author":"Dobson","year":"2022","journal-title":"J Pathol"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1182\/BLOOD-2013-04-496893","article-title":"EZH2 Mutations are Frequent and Represent an Early Event in Follicular Lymphoma","volume":"122","author":"B\u00f6d\u00f6r","year":"2013","journal-title":"Blood"},{"key":"B10","doi-asserted-by":"publisher","first-page":"181\u20135","DOI":"10.1038\/NG.518","article-title":"Somatic Mutations Altering EZH2 (Tyr641) in Follicular and Diffuse Large B-Cell Lymphomas of Germinal-Center Origin","volume":"42","author":"Morin","year":"2010","journal-title":"Nat Genet"},{"key":"B11","doi-asserted-by":"publisher","first-page":"1199\u20141208","DOI":"10.1038\/nm.3943","article-title":"The Histone Lysine Methyltransferase KMT2D Sustains a Gene Expression Program That Represses B Cell Lymphoma Development","volume":"21","author":"Ortega-Molina","year":"2015","journal-title":"Nat Med"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1002\/AJH.25696","article-title":"Follicular Lymphoma: 2020 Update on Diagnosis and Management","volume":"95","author":"Freedman","year":"2020","journal-title":"Am J Hematol"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1080\/08998280.2005.11928089","article-title":"Use of PET\/CT Scanning in Cancer Patients: Technical and Practical Considerations","volume":"18","author":"Griffeth","year":"2005","journal-title":"Proc (Bayl Univ Med Cent)"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1016\/J.IJROBP.2007.09.051","article-title":"Impact of [18f] Fluorodeoxyglucose Positron Emission Tomography on Staging and Management of Early-Stage Follicular Non-Hodgkin Lymphoma","volume":"71","author":"Wirth","year":"2008","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1097\/MNM.0B013E328334FC14","article-title":"False-Positive F-18 FDG Uptake in PET\/CT Studies in Pediatric Patients With Abdominal Burkitt\u2019s Lymphoma","volume":"31","author":"Riad","year":"2010","journal-title":"Nucl Med Commun"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1016\/J.CANCERGEN.2018.02.005","article-title":"Circulating Cell-Free DNA for non-Invasive Cancer Management","author":"Stewart","year":"2018","journal-title":"Cancer Genet"},{"key":"B17","doi-asserted-by":"publisher","first-page":"579\u2014586","DOI":"10.1200\/jco.2012.45.2011","article-title":"Liquid Biopsies: Genotyping Circulating Tumor DNA","volume":"32","author":"Diaz","year":"2014","journal-title":"J Clin Oncol"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-13-2482","article-title":"Noninvasive Detection of Response and Resistance in EGFR-Mutant Lung Cancer Using Quantitative Next-Generation Genotyping of Cell-Free Plasma DNA","volume":"20","author":"Oxnard","year":"2014","journal-title":"Clin Cancer Res"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-14-2666","article-title":"Androgen Receptor Gene Aberrations in Circulating Cell-Free DNA: Biomarkers of Therapeutic Resistance in Castration-Resistant Prostate Cancer","volume":"21","author":"Azad","year":"2015","journal-title":"Clin Cancer Res"},{"key":"B20","doi-asserted-by":"publisher","first-page":"2413\u20142425","DOI":"10.1182\/blood-2017-11-812073","article-title":"Circulating Tumor DNA Reveals Genetics, Clonal Evolution, and Residual Disease in Classical Hodgkin Lymphoma","volume":"131","author":"Spina","year":"2018","journal-title":"Blood"},{"key":"B21","doi-asserted-by":"publisher","first-page":"1947\u201457","DOI":"10.1182\/blood-2016-05-719641","article-title":"Diffuse Large B-Cell Lymphoma Genotyping on the Liquid Biopsy","volume":"129","author":"Rossi","year":"2017","journal-title":"Blood"},{"key":"B22","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/S12864-020-06848-9","article-title":"Quantitative Characterization of Tumor Cell-Free DNA Shortening","volume":"21","author":"Guo","year":"2020","journal-title":"BMC Genomics"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0001261","article-title":"Determinants of RNA Quality From FFPE Samples","volume":"2","author":"von Ahlfen","year":"2007","journal-title":"PloS One"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1182\/BLOOD-2014-04-571786","article-title":"BCL2 Mutations are Associated With Increased Risk of Transformation and Shortened Survival in Follicular Lymphoma","volume":"125","author":"Correia","year":"2015","journal-title":"Blood"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1073\/PNAS.1501199112","article-title":"Mutations in Early Follicular Lymphoma Progenitors are Associated With Suppressed Antigen Presentation","volume":"112","author":"Green","year":"2015","journal-title":"Proc Natl Acad Sci U S A"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1002\/PATH.4428","article-title":"Recurrent Mutations of NOTCH Genes in Follicular Lymphoma Identify a Distinctive Subset of Tumours","volume":"234","author":"Karube","year":"2014","journal-title":"J Pathol"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1182\/BLOOD-2013-05-500264","article-title":"Mutations in Linker Histone Genes HIST1H1 B, C, D, and E; OCT2 (POU2F2); IRF8; and ARID1A Underlying the Pathogenesis of Follicular Lymphoma","volume":"123","author":"Li","year":"2014","journal-title":"Blood"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1038\/NG.2856","article-title":"Integrated Genomic Analysis Identifies Recurrent Mutations and Evolution Patterns Driving the Initiation and Progression of Follicular Lymphoma","volume":"46","author":"Okosun","year":"2014","journal-title":"Nat Genet"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1182\/BLOOD-2012-09-457283","article-title":"Hierarchy in Somatic Mutations Arising During Genomic Evolution and Progression of Follicular Lymphoma","volume":"121","author":"Green","year":"2013","journal-title":"Blood"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1038\/NG.518","article-title":"Somatic Mutations Altering EZH2 (Tyr641) in Follicular and Diffuse Large B-Cell Lymphomas of Germinal-Center Origin","volume":"42","author":"Morin","year":"2010","journal-title":"Nat Genet"},{"key":"B31","doi-asserted-by":"publisher","first-page":"1994","DOI":"10.1182\/BLOOD.V82.7.1994.1994","article-title":"P53 Mutation Is Associated With Progression in Follicular Lymphomas","volume":"82","author":"Sander","year":"1993","journal-title":"Blood"},{"key":"B32","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1186\/s12859-017-1469-3","article-title":"AfterQC: Automatic Filtering, Trimming, Error Removing and Quality Control for Fastq Data","volume":"18","author":"Chen","year":"2017","journal-title":"BMC Bioinf"},{"key":"B33","first-page":"13033997","article-title":"Aligning Sequence Reads, Clone Sequences and Assembly Contigs With BWA-MEM","author":"Li","year":"2013","journal-title":"arXiv Prepr arXiv"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1093\/bioinformatics\/btp352","article-title":"The Sequence Alignment\/Map Format and SAMtools","volume":"25","author":"Li","year":"2009","journal-title":"Bioinformatics"},{"key":"B35","doi-asserted-by":"publisher","first-page":"213\u2014219","DOI":"10.1038\/nbt.2514","article-title":"Sensitive Detection of Somatic Point Mutations in Impure and Heterogeneous Cancer Samples","volume":"31","author":"Cibulskis","year":"2013","journal-title":"Nat Biotechnol"},{"key":"B36","doi-asserted-by":"publisher","first-page":"e164","DOI":"10.1093\/NAR\/GKQ603","article-title":"ANNOVAR: Functional Annotation of Genetic Variants From High-Throughput Sequencing Data","volume":"38","author":"Wang","year":"2010","journal-title":"Nucleic Acids Res"},{"key":"B37","doi-asserted-by":"publisher","first-page":"178\u2014192","DOI":"10.1093\/bib\/bbs017","article-title":"Integrative Genomics Viewer (IGV): High-Performance Genomics Data Visualization and Exploration","volume":"14","author":"Thorvaldsd\u00f3ttir","year":"2013","journal-title":"Brief Bioinform"},{"key":"B38","first-page":"28","article-title":"Package \u201cSurvival","volume":"128","author":"Therneau","year":"2015","journal-title":"R Top Doc"},{"key":"B39","article-title":"Package \u201cSurvminer","author":"Kassambara","year":"2017","journal-title":"Draw Surviv Curv using \u2018ggplot2\u2019(R Packag ver 03 1)"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.1039\/C5MB00663E","article-title":"ReactomePA: An R\/Bioconductor Package for Reactome Pathway Analysis and Visualization","volume":"12","author":"Yu","year":"2016","journal-title":"Mol Biosyst"},{"key":"B41","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/S41408-020-0335-0","article-title":"CREBBP and STAT6 Co-Mutation and 16p13 and 1p36 Loss Define the T (14;18)-Negative Diffuse Variant of Follicular Lymphoma","volume":"10","author":"Xian","year":"2020","journal-title":"Blood Cancer J"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.1371\/JOURNAL.PMED.1002197","article-title":"Histological Transformation and Progression in Follicular Lymphoma: A Clonal Evolution Study","volume":"13","author":"Kridel","year":"2016","journal-title":"PloS Med"},{"key":"B43","doi-asserted-by":"publisher","first-page":"130\u2014140","DOI":"10.1016\/j.celrep.2013.12.027","article-title":"Genetics of Follicular Lymphoma Transformation","volume":"6","author":"Pasqualucci","year":"2014","journal-title":"Cell Rep"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.1182\/BLOOD-2014-06-582650","article-title":"Activating STAT6 Mutations in Follicular Lymphoma","volume":"125","author":"Yildiz","year":"2015","journal-title":"Blood"},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.1038\/nrd4088","article-title":"Therapeutic Modulators of STAT Signalling for Human Diseases","volume":"12","author":"Miklossy","year":"2013","journal-title":"Nat Rev Drug Discov"},{"key":"B46","doi-asserted-by":"publisher","DOI":"10.1158\/1535-7163.MCT-13-0773","article-title":"Selective Inhibition of EZH2 by EPZ-6438 Leads to Potent Antitumor Activity in EZH2-Mutant non-Hodgkin Lymphoma","volume":"13","author":"Knutson","year":"2014","journal-title":"Mol Cancer Ther"},{"key":"B47","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(20)30441-1","article-title":"Tazemetostat for Patients With Relapsed or Refractory Follicular Lymphoma: An Open-Label, Single-Arm, Multicentre, Phase 2 Trial","volume":"21","author":"Morschhauser","year":"2020","journal-title":"Lancet Oncol"},{"key":"B48","doi-asserted-by":"publisher","DOI":"10.1007\/S00259-010-1539-5","article-title":"Diagnostic and Prognostic Impact of 18F-FDG PET\/CT in Follicular Lymphoma","volume":"37","author":"Le Dortz","year":"2010","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"B49","doi-asserted-by":"publisher","DOI":"10.1093\/ANNONC\/MDH406","article-title":"Predictive Value of Follicular Lymphoma International Prognostic Index (FLIPI) in Patients With Follicular Lymphoma at First Progression","volume":"15","author":"Montoto","year":"2004","journal-title":"Ann Oncol Off J Eur Soc Med Oncol"},{"key":"B50","doi-asserted-by":"publisher","DOI":"10.1002\/HON.2778","article-title":"Prognostic Significance of Histologic Grade and Ki-67 Proliferation Index in Follicular Lymphoma","volume":"38","author":"Xue","year":"2020","journal-title":"Hematol Oncol"},{"key":"B51","doi-asserted-by":"publisher","first-page":"1111\u201422","DOI":"10.1016\/s1470-2045(15)00169-2","article-title":"Integration of Gene Mutations in Risk Prognostication for Patients Receiving First-Line Immunochemotherapy for Follicular Lymphoma: A Retrospective Analysis of a Prospective Clinical Trial and Validation in a Population-Based Registry","volume":"16","author":"Pastore","year":"2015","journal-title":"Lancet Oncol"},{"key":"B52","doi-asserted-by":"publisher","first-page":"259\u2014267","DOI":"10.1111\/bjh.16159","article-title":"M7-FLIPI is Not Prognostic in Follicular Lymphoma Patients With First-Line Rituximab Chemo-Free Therapy","volume":"188","author":"Lockmer","year":"2020","journal-title":"Br J Haematol"},{"key":"B53","doi-asserted-by":"publisher","first-page":"298","DOI":"10.1038\/NATURE10351","article-title":"Frequent Mutation of Histone-Modifying Genes in non-Hodgkin Lymphoma","volume":"476","author":"Morin","year":"2011","journal-title":"Nature"},{"key":"B54","doi-asserted-by":"publisher","first-page":"7808\u20147815","DOI":"10.1158\/1078-0432.ccr-11-1712","article-title":"Quantitative Detection of EGFR Mutations in Circulating Tumor DNA Derived From Lung Adenocarcinomas","volume":"17","author":"Taniguchi","year":"2011","journal-title":"Clin Cancer Res"}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2022.870487\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,6,20]],"date-time":"2022-06-20T14:13:17Z","timestamp":1655734397000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2022.870487\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,6,16]]},"references-count":54,"alternative-id":["10.3389\/fonc.2022.870487"],"URL":"https:\/\/doi.org\/10.3389\/fonc.2022.870487","relation":{},"ISSN":["2234-943X"],"issn-type":[{"value":"2234-943X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,6,16]]},"article-number":"870487"}}